Pfizer Inc chief executive officer Jeffrey Kindler said his company can boost its late-stage experimental medicines by 50 percent next year as it implements strategies to make drug development more efficient.
Kindler, now in his second year as CEO of the world’s biggest drugmaker, has already eliminated jobs and factories to cut about US$2 billion in costs. He is now turning to Pfizer’s research laboratories and drug development units to see how the company can boost productivity.
“There is absolutely a need to be efficient across the industry in general and Pfizer is no exception,” Kindler said in an interview aired yesterday on Bloomberg television.
“We have looked at every program, every compound and made decisions to exit where we don’t see promise and to reinvest those savings,” he said.
Kindler is bracing New York-based Pfizer for generic competition in 2011 to its Lipitor cholesterol pill, the world’s top-selling drug with US$12.7 billion in sales last year. The drugmaker doesn’t have enough new products in development to replace the losses from Lipitor so Kindler is looking to trim expenses and squeeze more profit from existing products.
He’s also embarking on a strategy to make the pharmaceutical giant more nimble and “entrepreneurial,” by creating smaller units that “can move faster,” he said. Pfizer also is focusing on partnerships and alliances with biotechnology companies and smaller drugmakers.
Growth in the pharmaceutical industry is slowing, Kindler said in the interview. One way to be more efficient is to dismantle the “monolithic structure” of pharmaceutical research and development.
“I think growth rates are not going to be top-line double digit in the industry,” he said. “The problem of productivity in the industry is a significant one.”
ADVANCED: Previously, Taiwanese chip companies were restricted from building overseas fabs with technology less than two generations behind domestic factories Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), a major chip supplier to Nvidia Corp, would no longer be restricted from investing in next-generation 2-nanometer chip production in the US, the Ministry of Economic Affairs said yesterday. However, the ministry added that the world’s biggest contract chipmaker would not be making any reckless decisions, given the weight of its up to US$30 billion investment. To safeguard Taiwan’s chip technology advantages, the government has barred local chipmakers from making chips using more advanced technologies at their overseas factories, in China particularly. Chipmakers were previously only allowed to produce chips using less advanced technologies, specifically
The New Taiwan dollar is on the verge of overtaking the yuan as Asia’s best carry-trade target given its lower risk of interest-rate and currency volatility. A strategy of borrowing the New Taiwan dollar to invest in higher-yielding alternatives has generated the second-highest return over the past month among Asian currencies behind the yuan, based on the Sharpe ratio that measures risk-adjusted relative returns. The New Taiwan dollar may soon replace its Chinese peer as the region’s favored carry trade tool, analysts say, citing Beijing’s efforts to support the yuan that can create wild swings in borrowing costs. In contrast,
TARIFF SURGE: The strong performance could be attributed to the growing artificial intelligence device market and mass orders ahead of potential US tariffs, analysts said The combined revenue of companies listed on the Taiwan Stock Exchange and the Taipei Exchange for the whole of last year totaled NT$44.66 trillion (US$1.35 trillion), up 12.8 percent year-on-year and hit a record high, data compiled by investment consulting firm CMoney showed on Saturday. The result came after listed firms reported a 23.92 percent annual increase in combined revenue for last month at NT$4.1 trillion, the second-highest for the month of December on record, and posted a 15.63 percent rise in combined revenue for the December quarter at NT$12.25 billion, the highest quarterly figure ever, the data showed. Analysts attributed the
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) quarterly sales topped estimates, reinforcing investor hopes that the torrid pace of artificial intelligence (AI) hardware spending would extend into this year. The go-to chipmaker for Nvidia Corp and Apple Inc reported a 39 percent rise in December-quarter revenue to NT$868.5 billion (US$26.35 billion), based on calculations from monthly disclosures. That compared with an average estimate of NT$854.7 billion. The strong showing from Taiwan’s largest company bolsters expectations that big tech companies from Alphabet Inc to Microsoft Corp would continue to build and upgrade datacenters at a rapid clip to propel AI development. Growth accelerated for
RSS